ERYTECH Pharma S.A. ERYP
Jun 28, 2023, 3:48 PM EDT
52-week range unavailable
- Market cap
- 47.40M
- Revenue (ttm)
- 6.65M
- Profit margin
- -3.43%
- Shares out
- 60.75M
- Forward P/E
- -0.28
- Volume
- 3.21K
- Open
- 0.8195
- Previous close
- 0.78
- Day's range
- 0.78 – 0.84
- Beta
- 2.13
- Analysts
- Hold
- Price target
- 2.96 (+279.5%)
- Earnings date
- Apr 26, 2023
Key statistics
- Enterprise value
- -719.32K
- PEG ratio
- 0.00
- Price / sales
- 7.13
- Price / book
- 1.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 571.50%
- Free cash flow
- -21.08M
- Total cash
- 38.79M
- Total debt
- 13.57M
- Return on equity
- -0.98%
- Short % of float
- 0.00%
- 50-day average
- 0.859266
- 200-day average
- 0.743274
Analyst view
Consensus: hold
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 26, 2023
Expected Apr 26, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 26, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Mar 9, 2021 | Dec 1, 2020 | -1.00 | — | — | — |
| Mar 18, 2020 | Dec 1, 2019 | -0.86 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2017 | Cowen & Co. | init | — | Outperform |
About ERYTECH Pharma S.A.
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- erytech.com
News
Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript 
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why Is Erytech Pharma (ERYP) Stock Up 47% Today? 
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript - Why Cango Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday 
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
Your note
Sign in to keep a note on ERYP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.73% | 248,426 | 193.77K | Mar 30, 2023 |
| Millennium Management Llc | 0.09% | 30,802 | 24.02K | Mar 30, 2023 |
| Vanguard Personalized Indexing Management, LLC | 0.07% | 24,271 | 18.93K | Mar 30, 2023 |
| Mariner, LLC | 0.07% | 23,904 | 18.64K | Mar 30, 2023 |
| Virtu Financial LLC | 0.06% | 20,026 | 15.62K | Mar 30, 2023 |
| Citadel Advisors Llc | 0.03% | 10,807 | 8.43K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,542 | 1.98K | Feb 27, 2023 |